News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Real-time Estimate Cboe BZX Other stock markets 11:25:17 2024-04-16 am EDT			5-day change	1st Jan Change
67.58 ^USD	-0.25%		-3.40%	-16.60%

Apr. 15	Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76	MT
Apr. 10	Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	CI

Summary

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76	Apr. 15	MT
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	Apr. 09	CI
Morgan Stanley Cuts Price Target on Gilead Sciences to $80 From $83, Keeps Equalweight Rating	Apr. 09	MT
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024	Apr. 08	BU
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years	Apr. 02	MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration	Apr. 02	DJ
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences	Apr. 02	CI
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Top Midday Gainers	Apr. 01	MT
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	Apr. 01	MT
Top Premarket Gainers	Apr. 01	MT
Gilead Sciences Files a Definitive Proxy Statement	Mar. 28	CI
Gilead Sciences Files a Definitive Proxy Statement	Mar. 28	CI
Gilead Sciences Files a Definitive Proxy Statement	Mar. 28	CI
Gilead Sciences Inc Receives a Shareholder Proposal from David Bahnsen	Mar. 28	CI
Gilead Sciences Inc Receives a Shareholder Proposal from John Chevedden	Mar. 28	CI
Gilead Sciences Inc Receives a Shareholder Proposal from Jing Zhao	Mar. 28	CI
Xilio Shares Take Flight Premarket After Gilead Deal	Mar. 28	DJ
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	Mar. 28	MT
Gilead Says FDA Approves New Drug Application for Potential Hep-B Treatment for Smaller Children	Mar. 28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Summary

Filters